Importance of the co morbidities in the heart failure

Authors

  • Alfredo Enrique Arreddondo Bruce Hospital Clínico Quirúrgico Docente Amalia Simoni. Camagüey.
  • Fernando de Quezada López Hospital Clínico Quirúrgico Docente Amalia Simoni. Camagüey.
  • Gustavo Guerrero Jimenez Hospital Clínico Quirúrgico Docente Amalia Simoni. Camagüey.

Keywords:

heart failure, co-morbidities, diabetes mellitus, chronic pain, depression.

Abstract

Heart failure affects approximately 5.1 million adults in the USA, with expectations of a rise to nearly 8 million adults by 2030. Patients with heart failure are at increased risk for morbidity/mortality, and co-morbidities can further complicate care for these patients. Diabetes mellitus, chronic pain, and depression are diagnoses that often coexist with heart failure. Medications commonly used to treat these co-morbidities may induce or worsen heart failure symptoms, so determining appropriate drug therapy is important. Healthcare providers must understand the relationship between these medications and heart failure in order to improve prescribing practices to increase patient safety and reduce morbidity and mortality. This manuscript discusses the association between certain medications used to treat the aforementioned diagnoses and their relationship to heart failure. The purpose of this article is to provide guidance on which pharmacologic options require special consideration, increased monitoring, or complete avoidance in heart failure patients with diabetes mellitus, chronic pain, and/or depression.

Downloads

Download data is not yet available.

Published

2017-08-07

How to Cite

1.
Arreddondo Bruce AE, de Quezada López F, Guerrero Jimenez G. Importance of the co morbidities in the heart failure. Rev Méd Electrón [Internet]. 2017 Aug. 7 [cited 2025 Jan. 23];39(4):916-32. Available from: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/1691

Issue

Section

Review article

Most read articles by the same author(s)